BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20808143)

  • 1. (99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease.
    Devanand DP; Van Heertum RL; Kegeles LS; Liu X; Jin ZH; Pradhaban G; Rusinek H; Pratap M; Pelton GH; Prohovnik I; Stern Y; Mann JJ; Parsey R
    Am J Geriatr Psychiatry; 2010 Nov; 18(11):959-72. PubMed ID: 20808143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging.
    Jobst KA; Barnetson LP; Shepstone BJ
    Int Psychogeriatr; 1997; 9 Suppl 1():191-222; discussion 247-52. PubMed ID: 9447442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population.
    Scheltens P; Launer LJ; Barkhof F; Weinstein HC; Jonker C
    Alzheimer Dis Assoc Disord; 1997 Jun; 11(2):63-70. PubMed ID: 9194952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease.
    Encinas M; De Juan R; Marcos A; Gil P; Barabash A; Fernández C; De Ugarte C; Cabranes JA
    Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1473-80. PubMed ID: 14579086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT.
    Hirao K; Ohnishi T; Hirata Y; Yamashita F; Mori T; Moriguchi Y; Matsuda H; Nemoto K; Imabayashi E; Yamada M; Iwamoto T; Arima K; Asada T
    Neuroimage; 2005 Dec; 28(4):1014-21. PubMed ID: 16129627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla J; Portilla-Quattrociocchi H; Medina-Quiroz P; Ortega F; Rodríguez E; Mateo I; Vázquez-Higuera JL; de Arcocha M; Carril JM
    Rev Esp Med Nucl; 2011; 30(5):301-6. PubMed ID: 21640440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience.
    Johnson NA; Jahng GH; Weiner MW; Miller BL; Chui HC; Jagust WJ; Gorno-Tempini ML; Schuff N
    Radiology; 2005 Mar; 234(3):851-9. PubMed ID: 15734937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment.
    Habert MO; Horn JF; Sarazin M; Lotterie JA; Puel M; Onen F; Zanca M; Portet F; Touchon J; Verny M; Mahieux F; Giron A; Fertil B; Dubois B
    Neurobiol Aging; 2011 Jan; 32(1):15-23. PubMed ID: 19250707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.
    Devanand DP; Pradhaban G; Liu X; Khandji A; De Santi S; Segal S; Rusinek H; Pelton GH; Honig LS; Mayeux R; Stern Y; Tabert MH; de Leon MJ
    Neurology; 2007 Mar; 68(11):828-36. PubMed ID: 17353470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain SPECT in subtypes of mild cognitive impairment. Findings from the DESCRIPA multicenter study.
    Nobili F; Frisoni GB; Portet F; Verhey F; Rodriguez G; Caroli A; Touchon J; Calvini P; Morbelli S; De Carli F; Guerra UP; Van de Pol LA; Visser PJ
    J Neurol; 2008 Sep; 255(9):1344-53. PubMed ID: 18958573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease.
    Alegret M; Cuberas-Borrós G; Vinyes-Junqué G; Espinosa A; Valero S; Hernández I; Roca I; Ruíz A; Rosende-Roca M; Mauleón A; Becker JT; Castell-Conesa J; Tárraga L; Boada M
    J Alzheimers Dis; 2012; 30(1):109-20. PubMed ID: 22406443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: a SPECT blood flow study.
    Brown DR; Hunter R; Wyper DJ; Patterson J; Kelly RC; Montaldi D; McCullouch J
    J Psychiatr Res; 1996; 30(2):109-26. PubMed ID: 8816305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.
    Mosconi L; Perani D; Sorbi S; Herholz K; Nacmias B; Holthoff V; Salmon E; Baron JC; De Cristofaro MT; Padovani A; Borroni B; Franceschi M; Bracco L; Pupi A
    Neurology; 2004 Dec; 63(12):2332-40. PubMed ID: 15623696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment.
    Huang C; Wahlund LO; Svensson L; Winblad B; Julin P
    BMC Neurol; 2002 Sep; 2():9. PubMed ID: 12227833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional cerebral blood flow differences in patients with mild cognitive impairment between those who did and did not develop Alzheimer's disease.
    Park KW; Yoon HJ; Kang DY; Kim BC; Kim S; Kim JW
    Psychiatry Res; 2012; 203(2-3):201-6. PubMed ID: 22980226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease.
    Nobili F; Brugnolo A; Calvini P; Copello F; De Leo C; Girtler N; Morbelli S; Piccardo A; Vitali P; Rodriguez G
    Clin Neurophysiol; 2005 Feb; 116(2):364-75. PubMed ID: 15661114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
    Devanand DP; Pelton GH; Zamora D; Liu X; Tabert MH; Goodkind M; Scarmeas N; Braun I; Stern Y; Mayeux R
    Arch Neurol; 2005 Jun; 62(6):975-80. PubMed ID: 15956169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMPAO-SPECT Can Discriminate between Patients with Subjective Cognitive Complaints with and without Cognitive Deficits and those with Mild Cognitive Impairment.
    Rossini F; Zauner H; Bergmann J; Kronbichler M; Spindler I; Golaszewski S; Trinka E; Staffen W
    Curr Alzheimer Res; 2019; 16(9):843-851. PubMed ID: 31453786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HM-PAO (CERETEC) SPECT brain scanning in the diagnosis of Alzheimer's disease.
    Bergman H; Chertkow H; Wolfson C; Stern J; Rush C; Whitehead V; Dixon R
    J Am Geriatr Soc; 1997 Jan; 45(1):15-20. PubMed ID: 8994482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging.
    Jobst KA; Barnetson LP; Shepstone BJ
    Int Psychogeriatr; 1998 Sep; 10(3):271-302. PubMed ID: 9785148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.